Wednesday
October
22
2014
9:33 pm
Weather

  Home
  Local News
  State / National / World
  Sports
  Opinion / Letters
  Business
  Arts / Entertainment
  Lifestyle
  Obituaries
  Calendar
  Submit Event
  Comics / Games
  Classifieds
  DJ Designers
  Archives
  Advertise With Us
  About Us
 
 
 
 

Check out our archive of Dining Guides - Yum!

Allergan to cut 1,500 employees in restructuring
July 22, 2014, 05:00 AM By Tom Murphy The Associated

Botox maker Allergan will cut about 13 percent of its workforce as part of a push to become more efficient while it fights a hostile takeover bid from Valeant Pharmaceuticals.

The Irvine, California, company said Monday it plans to trim about 1,500 employees and around 250 vacant positions as it restructures to focus on its “highest value opportunities.”

Allergan said its restructuring will yield annual pretax savings of about $475 million in 2015. It announced the cuts the same day it said second-quarter results trumped analyst expectations, as earnings grew 16 percent to $417.2 million.

“Today’s results demonstrate that we’re clearly on the right path,” Chairman and CEO David Pyott told analysts during a conference call. “The actions announced today will only accelerate our trajectory.”

Allergan Inc. has rejected several takeover attempts from Valeant Pharmaceuticals International Inc. and activist investor Bill Ackman’s Pershing Square Capital Management. The latest amounts to about $53 billion in cash and stock.

Valeant has promised cost-cutting and savings of its own if the two companies combine. Ackman, whose company owns a 9.7 percent stake in Allergan, told CNBC that shareholders had been asking for Allergan cost-cutting for some time. He said the reductions that the company announced Monday amounted to “cutting out fat you should have cut out a long time ago.”

“Allergan can only achieve so much as a stand-alone company,” he said.

Ackman has lined up nominees for Allergan’s board, and Pershing Square wants to hold a special meeting where Allergan shareholders can have a say in the buyout bid and on the company’s direction.

Allergan, which also makes the dry-eye treatment Restasis, has adopted a “poison pill” measure to block a takeover. Pyott said Monday that Valeant’s offer was “so far away from the intrinsic value of this company” that there was no reason for the drugmakers to have substantive talks.

Allergan and Valeant have feuded publicly over the possible takeover since April. In the latest twist, Valeant said Monday it has complained to both the Securities and Exchange Commission and authorities in the Canadian province of Quebec, where it is based, that Allergan has been making false statements about its business even though Valeant has publicly corrected it.

Valeant said the latest example of these statements involves the performance of contact lens maker Bausch + Lomb, which Valeant acquired last year.

“We can no longer tolerate unjustified attacks on Valeant’s business and strongly believe we are obligated to take action to protect Valeant shareholders from Allergan’s apparent attempts to mislead investors and manipulate the market for Valeant stock,” Valeant Chairman and CEO J. Michael Pearson said in a statement from the company.

An Allergan spokesman responded by email that the company stood by its comments.

“We call on Valeant to report complete and transparent details on its business on an ongoing basis,” the spokesman said. “At the end of the day, investors will make their own decisions.”

The drugmaker also said on Monday that it raised its forecast for adjusted 2014 earnings to between $5.74 and $5.80 per share from a range of $5.64 to $5.73 that it predicted in May. It expects Botox to deliver net sales ranging from $2.2 billion to $2.28 billion.

Botox is known best for its ability to smooth frown lines on aging foreheads, but it also is approved to treat neck spasms, eye muscle disorders, migraines and other conditions.

Shares of Allergan climbed 2.3 percent, or $3.90, to $171.30 Monday afternoon, while U.S.-traded shares of Valeant also were up 3 percent, or $3.69, to $125.66.

 

 

Tags: valeant, allergan, monday, company, about, percent,


Other stories from today:

Law OKs underage wine and beer tasting in colleges
Beef pollutes more than pork, poultry, study says
Report: Retaliation by supervisors common at VA
 

 
Print this Page Print this Page  |  Bookmark and Share
<< Back
 
Return To Archives
 
  


 
 
 
Daily Journal Quick Poll
 
Does the terrorist attack near the Canadian Parliament concern you?

Yes, extremely
Yes, somewhat
A little
Not at all

 

 
 
 
 
 
 
Giants fans be wary, man robbed of World Series tickets worth $1,000
With the World Series hot on San Francisco Giants’ fans minds, police are reminding people to be w..
Two dead in shooting attack at Canada's Parliament
OTTAWA, Ontario — A gunman with a scarf over his face shot to death a Canadian soldier standin..
US to track everyone coming from Ebola nations
WASHINGTON — Stepping up their vigilance against Ebola, federal authorities said Wednesday that ev..
Government ups air bag warning to 7.8M vehicles
DETROIT — The U.S. government is telling 3 million more car owners to get their air bags repaired ..
Turkish president says US airdrop to Kurds in Kobani a mistake
ISTANBUL — Turkish President Recep Tayyip Erdogan says that the U.S. made a mistake in airdropping..
More >>  
 
 
  
 
  
 
©2014 San Mateo Daily Journal
San Mateo County crime